Blogroll
Link
- Argentinean Network of Women Living with HIV-AIDS
- Asia Pacific Network of People Living with HIV/AIDS
- bilaterals.org
- Cambodian People Living with HIV/AIDS Network (CPN+)
- Delhi Network of Positive People (DNP+)
- Essentialdrugs.org
- FACEBOOK PAGE: Stop the EU India Free Trade Agreement
- FTA Malaysia
- Health Action International – Asia Pacific
- Intellectual Property Watch
- Lawyers Collective HIV/AIDS Unit
- MSF Access Campaign
- National Association of People Living with HIV and AIDS in Nepal (NAPN)
- Patent Opposition Database
- Public Citizen
- Stop Peru FTA
- Thai Network of People Living with HIV/Aids (TNP+)
- Third World Network
Take Action
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
-
Recent Posts
- Trans-Pacific Partnership: Trade Agreement or Anti-China Alliance?
- WHO: Concerns over draft text on R&D financing and coordination
- The Transatlantic Free Trade Agreement: It’s About the Big Picture
- TRIPping Up Least Developed Countries on Medicines, Green Tech, and Textbooks?
- Live from the Trans Pacific Partnership: IP Chapter Shows No Sign of Resolution, End of Negotiation in 2013 Highly Unlikely
Categories
Category Archives: Novartis Case
Doctors Denounce Cancer Drug Prices of $100,000 a Year
Source: New York Times April 25,2013 With the cost of some lifesaving cancer drugs exceeding $100,000 a year, more than 100 influential cancer specialists from around the world have taken the unusual step of banding together in hopes of persuading some leading … Continue reading
Posted in access to medicines, Generic drug, Novartis Case, patent
Tagged Imatinib, Novartis
1 Comment
India must protect access to medicine
Source: Livemint April 22,2013 India needs to safeguard its vital interests in any trade agreement, the way other nations do Is India committed to protecting access to essential medicines for its citizens? Several recent developments have generated national and international debate … Continue reading
South Africa seeks to close drug patent loophole
Source: Healthnexercise April 23, 2013 By Wendell Roelf CAPE TOWN (Reuters) – South Africa plans to overhaul its intellectual property laws to improve access to cheaper medicines by making it harder for pharmaceutical firms to register and roll-over patents for … Continue reading
The Larger Implications of the Novartis-Glivec Judgment
Source: Economic and Political Weekly Vol XLVIII No.17 by Sudip Chaudhari April 27,2013 The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in … Continue reading
Posted in access to medicines, Compulsory Licensing, Generic drug, IP Rights, Novartis Case, patent, patent evergreening, Sec 3 (d), TRIPS, WTO
Tagged Imatinib, Novartis, Patent, Supreme court
Leave a comment
R&D: What Novartis says . . . and why it’s wrong
Source: Livemint April 12,2013 Increasing evidence over the last decade has pointed to the patent system being a bottleneck for research itself and access to affordable medicines.
EU-India FTA trade talks kick off with new momentum
Source: Economic Times BRUSSELS: Long-running talks on an EU Free Trade Agreement with India gained fresh momentum in a meeting Monday with Indian Commerce Minister Anand Sharma, the European Commission said. EU Trade Commissioner De Gucht and Sharma “had a positive meeting which has provided … Continue reading
Posted in EU-India FTA, Novartis Case, TRIPS
Tagged European Commissioner for Trade, European Union, India, Novartis
Leave a comment
Why are our medicines so expensive?
Source:euobserver BY ELS TORREELE BRUSSELS - In the lead-up to an inter ministerial meeting between EU and India next week, European trade negotiators continue to pressure India and other developing countries to accept so-called “free trade” agreements that favour patent monopolies, … Continue reading
‘Novartis case: Supreme Court ruling wise and balanced’
Source: Rediff April 10,2013 The Supreme Court recently rejected the plea of Novartis [ Get Quote ] AG for patent protection of its anti-cancer drug Glivec. The Supreme Court judgement (pages 22 -26) quite extensively quoted from Sudip Chaudhuri’s bookThe WTO and India’s … Continue reading
Selling India’s health to the EU
Source: Avaaz 8th April,2013 In days, India’s position as the world’s pharmacy may be overturned. But we can persuade Commerce Minister Sharma to save our industry and protect patients everywhere.
